We are live on ! Find out more
RCOR

Renovacor, Inc.

Delisted

RCOR was delisted on the 30th of November, 2022.

 

About: Renovacor Inc is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Its therapeutic focus is on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy.

Employees: 19

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 0%
Neutral 0%
Negative 0%

We haven’t received any recent news articles for RCOR

Price charts implemented using Lightweight Charts™